PRCC
višeznačna odrednica na Wikimediji
Prolinom-bogati protein PRCC jest protein koji je kod ljudi kodiran genom PRCC sa hromosoma 1.[1][2]
| PRCC | |||||||
|---|---|---|---|---|---|---|---|
| Identifikatori | |||||||
| Aliasi | |||||||
| Vanjski ID-jevi | GeneCards: [1] | ||||||
| Ortolozi | |||||||
| Vrste | Čovjek | Miš | |||||
| Entrez |
|
| |||||
| Ensembl |
|
| |||||
| UniProt |
| ||||||
| RefSeq (mRNK) |
|
| |||||
| RefSeq (bjelančevina) |
|
| |||||
| Lokacija (UCSC) | n/a | n/a | |||||
| PubMed pretraga | n/a | n/a | |||||
| Wikipodaci | |||||||
| |||||||
Aminokiselinska sekvenca
urediDužina polipeptidnog lanca je 491 aminokiselina, a molekulska težina 52.418 Da.[3]
| 10 | 20 | 30 | 40 | 50 | ||||
|---|---|---|---|---|---|---|---|---|
| MSLVAYASSD | ESEPDEAEPE | PEEEEAVAPT | SGPALGGLFA | SLPAPKGPAL | ||||
| LPPPPQMLAP | AFPPPLLLPP | PTGDPRLQPP | PPLPFGLGGF | PPPPGVSPAE | ||||
| AAGVGEGLGL | GLPSPRGPGL | NLPPPIGGAG | PPLGLPKPKK | RKEPVKIAAP | ||||
| ELHKGDSDSE | EDEPTKKKTI | LQGSSEGTGL | SALLPQPKNL | TVKETNRLLL | ||||
| PHAFSRKPSD | GSPDTKPSRL | ASKTKTSSLA | PVVGTTTTTP | SPSAIKAAAK | ||||
| SAALQVTKQI | TQEEDDSDEE | VAPENFFSLP | EKAEPPGVEP | YPYPIPTVPE | ||||
| ELPPGTEPEP | AFQDDAANAP | LEFKMAAGSS | GAPWMPKPGD | DYSYNQFSTY | ||||
| GDANAAGAYY | QDYYSGGYYP | AQDPALVPPQ | EIAPDASFID | DEAFKRLQGK | ||||
| RNRGREEINF | VEIKGDDQLS | GAQQWMTKSL | TEEKTMKSFS | KKKGEQPTGQ | ||||
| QRRKHQITYL | IHQAKERELE | LKNTWSENKL | SRRQTQAKYG | F |
Funkcija
urediU podskupini papilskih karcinoma bubrežnih ćelija, t(X;1)(p11;q21) translokacija hromosoma je više puta prijavljivana i smatra se da je uzrok raka. Kao rezultat translokacije, faktor transkripcije TFE3 na X-hromosomu postaje spojen sa ovim genom na hromosomu 1. Spojeni gen rezultira fuzijom N-terminalne regije bogate prolinkim proteinima, koji je kodiran ovim genom sa cijelim proteinom TFE3.
Pokazalo se da ovaj protein interraguje sa proteinom mitotske kontrolne tačke MAD2B, što sugeriše da dominantno-negativni efekt fuzijsog proteina sa TFE3 može dovesti do defekta mitotske kontrolne tačke. Uočene su alternativno prerađene varijante transkripta koje kodiraju različite izoforme.[2]
Reference
uredi- ^ Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, Ross M, Linehan WM, Birdsall S, Shipley J, Cooper CS (Jan 1997). "The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene". Hum Mol Genet. 5 (9): 1333–8. doi:10.1093/hmg/5.9.1333. PMID 8872474.
- ^ a b "Entrez Gene: PRCC papillary renal cell carcinoma (translocation-associated)".
- ^ "UniProt, Q92733" (jezik: engleski). Pristupljeno 16. 12. 2021.
Dopunska literatura
uredi- Zbar B, Glenn G, Lubensky I, et al. (1995). "Hereditary papillary renal cell carcinoma: clinical studies in 10 families". J. Urol. 153 (3 Pt 2): 907–12. doi:10.1016/S0022-5347(01)67601-8. PMID 7853572.
- Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993). "Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic subtype". Cancer Genet. Cytogenet. 65 (1): 1–6. doi:10.1016/0165-4608(93)90050-V. PMID 8431910.
- Weterman MA, Wilbrink M, Geurts van Kessel A (1997). "Fusion of the transcription factor TFE3 gene to a novel gene, PRCC, in t(X;1)(p11;q21)-positive papillary renal cell carcinomas". Proc. Natl. Acad. Sci. U.S.A. 93 (26): 15294–8. doi:10.1073/pnas.93.26.15294. PMC 26398. PMID 8986805.
- Weterman MJ, van Groningen JJ, Jansen A, van Kessel AG (2000). "Nuclear localization and transactivating capacities of the papillary renal cell carcinoma-associated TFE3 and PRCC (fusion) proteins". Oncogene. 19 (1): 69–74. doi:10.1038/sj.onc.1203255. PMID 10644981.
- Skalsky YM, Ajuh PM, Parker C, et al. (2001). "PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors". Oncogene. 20 (2): 178–87. doi:10.1038/sj.onc.1204056. PMID 11313942.
- Weterman MA, Wilbrink M, Eleveld M, et al. (2001). "Genomic structure, chromosomal localization, and embryonic expression of the mouse homolog of PRCC, a gene associated with papillary renal cell carcinoma". Cytogenet. Cell Genet. 92 (3–4): 326–32. doi:10.1159/000056922. PMID 11435707. S2CID 2520925.
- Weterman MA, van Groningen JJ, Tertoolen L, van Kessel AG (2002). "Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas". Proc. Natl. Acad. Sci. U.S.A. 98 (24): 13808–13. doi:10.1073/pnas.241304198. PMC 61123. PMID 11717438.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs". Nat. Genet. 36 (1): 40–5. doi:10.1038/ng1285. PMID 14702039.
- Anderson NL, Polanski M, Pieper R, et al. (2004). "The human plasma proteome: a nonredundant list developed by combination of four separate sources". Mol. Cell. Proteomics. 3 (4): 311–26. doi:10.1074/mcp.M300127-MCP200. PMID 14718574.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Olsen JV, Blagoev B, Gnad F, et al. (2006). "Global, in vivo, and site-specific phosphorylation dynamics in signaling networks". Cell. 127 (3): 635–48. doi:10.1016/j.cell.2006.09.026. PMID 17081983. S2CID 7827573.